A solvent-free method to extract THCA from cannabis, said method comprising: providing a source of THCA-containing cannabis plant; providing a source of natural oil; combining said source of THCA-containing cannabis and said source of natural oil into a blend; milling said blend; optionally, heating the blend during the milling; and extracting a THCA-containing liquid generated during the milling.

An extraction method of proanthocyanidins from Myrica rubra Sieb. Et Zucc leaves is provided. In the method, proanthocyanidins from Myrica rubra Sieb. Et Zucc leaf are obtained by preparing an aqueous Myrica rubra Sieb. Et Zucc leaf suspension and centrifuging. In the method, only water is used as an extraction reagent without introduction of an organic extraction solvent, which reduces costs and is free from environmental pollution; moreover, the method does not cause organic reagent residue in a product, such that the biological activity of the proanthocyanidins is not affected and product safety is improved without affecting product quality; meanwhile, extraction steps are simplified, extraction time is reduced and extraction efficiency is improved. The method provides stability, good reproducibility, simple equipment and easy control of conditions.

To improve the emission efficiency, the driving voltage and the lifetime of an organic light-emitting device using a delayed fluorescent material. A host material for a delayed fluorescent material, containing a compound represented by the following general formula: R.sup.1 to R.sup.5 each are a substituent not containing a cyano group. n1 to n5 each are 0 to 4, Ar is a monocyclic arylene group or a monocyclic heteroarylene group.

##STR00001##

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof ##STR00001##
wherein Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.

Near infrared and shortwave infrared dyes can have polymethine structures.

A solvent-free method to extract THCA from cannabis, said method comprising: providing a source of THCA-containing cannabis plant; providing a source of natural oil; combining said source of THCA-containing cannabis and said source of natural oil into a blend; milling said blend; optionally, heating the blend during the milling; and extracting a THCA-containing liquid generated during the milling.

A solvent-free method to extract THCA from cannabis, said method comprising: providing a source of THCA-containing cannabis plant; providing a source of natural oil; combining said source of THCA-containing cannabis and said source of natural oil into a blend; milling said blend; optionally, heating the blend during the milling; and extracting a THCA-containing liquid generated during the milling.

Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

The present invention provides an epigallocatechin gallate derivative (EGCG derivative) that has excellent safety and antibacterial properties. An epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is used as an antibacterial agent. In the formula, R.sup.1 to R.sup.6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of the R.sup.1 to R.sup.6 is the acyl group. R.sup.7 to R.sup.16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another. ##STR00001##